217 related articles for article (PubMed ID: 20840734)
1. A systems biology approach to identify effective cocktail drugs.
Wu Z; Zhao XM; Chen L
BMC Syst Biol; 2010 Sep; 4 Suppl 2(Suppl 2):S7. PubMed ID: 20840734
[TBL] [Abstract][Full Text] [Related]
2. Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes.
Rosenstock J; Rood J; Cobitz A; Biswas N; Chou H; Garber A
Diabetes Obes Metab; 2006 Nov; 8(6):650-60. PubMed ID: 17026489
[TBL] [Abstract][Full Text] [Related]
3. Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes.
Zinman B; Haffner SM; Herman WH; Holman RR; Lachin JM; Kravitz BG; Paul G; Jones NP; Aftring RP; Viberti G; Kahn SE;
J Clin Endocrinol Metab; 2010 Jan; 95(1):134-42. PubMed ID: 19875477
[TBL] [Abstract][Full Text] [Related]
4. Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study.
Zinman B; Harris SB; Neuman J; Gerstein HC; Retnakaran RR; Raboud J; Qi Y; Hanley AJ
Lancet; 2010 Jul; 376(9735):103-11. PubMed ID: 20605202
[TBL] [Abstract][Full Text] [Related]
5. Comparison of metformin, gliclazide MR and rosiglitazone in monotherapy and in combination for type 2 diabetes.
Vilar L; Canadas V; Arruda MJ; Arahata C; Agra R; Pontes L; Montenegro L; Vilar CF; Silva LM; Albuquerque JL; Gusmão A
Arq Bras Endocrinol Metabol; 2010 Mar; 54(3):311-8. PubMed ID: 20520962
[TBL] [Abstract][Full Text] [Related]
6. Rosiglitazone maleate/metformin hydrochloride: a new formulation therapy for type 2 diabetes.
Cox SL
Drugs Today (Barc); 2004 Jul; 40(7):633-43. PubMed ID: 15510236
[TBL] [Abstract][Full Text] [Related]
7. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
8. Drug interactions of clinical importance with antihyperglycaemic agents: an update.
Scheen AJ
Drug Saf; 2005; 28(7):601-31. PubMed ID: 15963007
[TBL] [Abstract][Full Text] [Related]
9. A clinical trial to maintain glycemic control in youth with type 2 diabetes.
; Zeitler P; Hirst K; Pyle L; Linder B; Copeland K; Arslanian S; Cuttler L; Nathan DM; Tollefsen S; Wilfley D; Kaufman F
N Engl J Med; 2012 Jun; 366(24):2247-56. PubMed ID: 22540912
[TBL] [Abstract][Full Text] [Related]
10. Effects of pioglitazone and rosiglitazone combined with metformin on body weight in people with diabetes.
Derosa G; Tinelli C; Maffioli P
Diabetes Obes Metab; 2009 Dec; 11(12):1091-9. PubMed ID: 19765050
[TBL] [Abstract][Full Text] [Related]
11. Pioglitazone and metformin.
Hill NR; Matthews DR
Drugs Today (Barc); 2007 Jul; 43(7):443-54. PubMed ID: 17728845
[TBL] [Abstract][Full Text] [Related]
12. Comparison of fixed-dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight individuals with Type 2 diabetes inadequately controlled on metformin alone.
Hamann A; Garcia-Puig J; Paul G; Donaldson J; Stewart M
Exp Clin Endocrinol Diabetes; 2008 Jan; 116(1):6-13. PubMed ID: 18095238
[TBL] [Abstract][Full Text] [Related]
13. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.
Derosa G; Cicero AF; Gaddi A; Ragonesi PD; Fogari E; Bertone G; Ciccarelli L; Piccinni MN
Clin Ther; 2004 May; 26(5):744-54. PubMed ID: 15220018
[TBL] [Abstract][Full Text] [Related]
14. Thiazolidinedione derivatives in type 2 diabetes mellitus.
Tack CJ; Smits P
Neth J Med; 2006 Jun; 64(6):166-74. PubMed ID: 16788214
[TBL] [Abstract][Full Text] [Related]
15. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.
Derosa G; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Montagna L; Gravina A; Ferrari I; Paniga S; Cicero AF
J Clin Pharm Ther; 2006 Aug; 31(4):375-83. PubMed ID: 16882108
[TBL] [Abstract][Full Text] [Related]
16. Development of heart failure in Medicaid patients with type 2 diabetes treated with pioglitazone, rosiglitazone, or metformin.
Breunig IM; Shaya FT; McPherson ML; Snitker S
J Manag Care Spec Pharm; 2014 Sep; 20(9):895-903. PubMed ID: 25166288
[TBL] [Abstract][Full Text] [Related]
17. Pioglitazone/metformin.
Deeks ED; Scott LJ
Drugs; 2006; 66(14):1863-77; discussion 1878-80. PubMed ID: 17040116
[TBL] [Abstract][Full Text] [Related]
18. Effects of metformin and rosiglitazone on peripheral insulin resistance and β-cell function in obesity: a double-blind, randomized, controlled study.
Li X; Zhang N; Li Y; Shi Y; Li D; Xie Y; Xie Y; Ming J
J Int Med Res; 2011; 39(2):358-65. PubMed ID: 21672339
[TBL] [Abstract][Full Text] [Related]
19. Assessment of the relative effectiveness and tolerability of treatments of type 2 diabetes mellitus: a network meta-analysis.
Zintzaras E; Miligkos M; Ziakas P; Balk EM; Mademtzoglou D; Doxani C; Mprotsis T; Gowri R; Xanthopoulou P; Mpoulimari I; Kokkali C; Dimoulou G; Rodopolou P; Stefanidis I; Kent DM; Hadjigeorgiou GM
Clin Ther; 2014 Oct; 36(10):1443-53.e9. PubMed ID: 25109773
[TBL] [Abstract][Full Text] [Related]
20. Cancer and bone fractures in observational follow-up of the RECORD study.
Jones NP; Curtis PS; Home PD
Acta Diabetol; 2015 Jun; 52(3):539-46. PubMed ID: 25524432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
